INMB INMUNE BIO INC Other Situations 8-K Filing 2024 - Announcement of Phase I/II Trial Dosing INmune Bio Inc. announced the dosing of the first patient in their INKmune Phase I/II trial for metastatic castration-resistant prostate cancer.Get access to all SEC 8-K filings of the INMUNE BIO INC